Janux Therapeutics, Inc. Payments for Repurchase of Initial Public Offering
Janux Therapeutics, Inc. (JANX) reported Payments for Repurchase of Initial Public Offering of $0 for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2022-05-10
- Janux Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Janux Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-03-31 was $100.00K.
| Period end | Payments for Repurchase of Initial Public Offering 3 month |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 |
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |